Elan: AGM notes - 500 Beiträge pro Seite

[Cyberhexe]

5/26/05
5am EST US

Kyan McLaughlan, Chairman

We take serious our responsibilities
We are confident of full potential
Need to balance near-term and long term goals
The board has full confidence in KM.



Kelly Martin, CEO

We are for: patients, shareholders, employees, regulators, biogen, wyeth.



Areas of focus short term

1) Tysabri

a) return to marketplace

b) reg advancement in EU crohn’s ms

c) reg advancement in US crohn’s

d) New autoimmune areas (UC, asthma organ transplant and others)

e) Discussions with FDA

i) comprehensive by mid to late summer

ii) All 3k by then, risk benefits approach laid out and path forward



2) Balance Sheet

a) Need flexibility to accomplish goals

b) Last year’s reduction of complexity achieved

i) Currently No JVs

c) 2008 debt due is non-concern, can growth other parts of business



3) Advance development

a) Phase II ALZ program started 6 weeks ago

i) Disease modifying progress… nothing comes close

b) Prialt Launch in US

c) Drug Technology business

i) Nano, Athlone, Gainesville

ii) Now using nano tech patents to work with marketplace

iii) Doubled net income year over year

iv) Future is extremely, extremely bright

d) US Hospital sales force still in place intend to leverage over time



Main long term objectives

1) Pre-clinical research one of innovation and discovery

a) Dementia and mild cognitive impairment

b) ALZ family of treatments

c) Autoimmune spinoffs (Ty is one of them)

i) Now have follow on generations

(1) 3-18 months will become visible

ii) PD and HD

2) Innovative business models

a) GLOBAL focus

i) China and India

ii) Research model extension

b) Drug technology

i) See it allowing ELN to become a primary care pharmaceutical company without infrastructure.

1. “Royalty from modified formulations”

2. Significant prospects for this franchise

3) Risk management

a) This is a risky business

i) Seek to understand and limit it, diversification, less volatility

ii) DD is an example

(1) Reduces need for science and discovery and increases cash flow to the company

[Cyberhexe]

interessant:

http://www.thisisms.com/modules.php?name=News&file=article&s…

[Mr Ti]

und der kurs gestern unterstreicht das positive nur so und jetzt kann jeder entscheiden, ob man noch in den zug einsteigt, den das gap ist noch nicht geschlossen.

wunderschönes wochenende @ all